TCR2 Therapeutics Inc. (NASDAQ: TCRR) has announced its manufacturing capacity expansion through the exercise of an option on a second cleanroom at ElevateBio BaseCamp, adding to the clinical buildout and commercial supply ongoing at its Rockville, MD facility.
Demand increased in 2022 because TC-510 and Phase 2 gavo cel study start
The additional supply at ElevateBio BaseCamp coincides with an expected increase in demand in 2022 due to the start of Phase 1 clinical trial for TC-510, a mesothelin TRuC-T cell enhanced with a PD1xCD28 switch, and the Phase 2 clinical trial of gavo-cel for mesothelin-expressing solid tumors. In addition, TCR2 clinical and commercial supply’s long-term goal is to grow its 85,000-square-foot Rockville plant as a manufacturing center in the United States. TCR2 wants to stop manufacturing at the Cell and Gene Therapy Catapult (CGT Catapult) in Stevenage, UK, as part of this expansion.
CEO and President Garry Menzel said, “This increase in cGMP manufacturing capacity at ElevateBio BaseCamp will ensure we are able to execute on the gavo-cel Phase 2 trial and the clinical plans for our next-generation TRuC-T cell products. We are excited by the therapeutic potential of our lead clinical therapy gavo-cel and the emerging solid tumor pipeline reviewed recently at our R&D Day. Our strategy remains focused on continuous innovation providing multiple opportunities to save the lives of cancer patients.
TCR2 uses TCR Fusion Construct T cells to target solid tumors
TCR2 Therapeutics Inc. (NASDAQ: TCRR) is a clinical-stage cell therapy firm working on a pipeline of new T cell treatments for solid tumor patients. Using its unique TCR Fusion Construct T cells (TRuC®-T cells), the company is focusing on the development and discovery of product candidates against novel and difficult targets. The TRuC platform, which is independent of human leukocyte antigens, is meant to identify and kill cancer cells by harnessing signals from the complete TCR.
